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Abstract
Background: This study aimed to determine the socioeconomic and clinical characteristics affecting health-related
quality of life (HRQoL) in patients with psoriasis.
Methods: A cross-sectional study was conducted between March and June 2015 using data obtained via an
Internet-based survey completed by a psoriasis patient group in Korea. The survey included items regarding
demographic, socioeconomic, and clinical characteristics and HRQoL. Patients’ HRQoL impairment was classified as
severe if their Dermatology Life Quality Index Scores were≥ 11. Factors influencing HRQoL impairment were identified
using multivariate logistic regression analysis.
Results: Of the 299 respondents, 161 (53.8%) exhibited severe HRQoL impairment. The Dermatology Life Quality Index
scores were significantly associated with gender, annual income, neck psoriasis, psoriasis-related resignation from work,
and use of oral and herbal medications. The severity of HRQoL impairment in women was twice that observed in men
(odds ratio [OR] = 2.00, 95% confidence interval (CI): 1.05–3.80). Patients with psoriasis on the neck exhibited
significantly greater HRQoL impairment than those with psoriasis on other areas of their bodies (OR = 2.30, 95% CI:
1.20–4.43). With respect to the socioeconomic status, patients who earned > 40 million KRW (approximately 34,000
USD; high-income group) showed less HRQoL impairment compared with those who had lower incomes (OR = 0.47,
95% CI: 0.28–0.80). Patients with severe HRQoL impairment used oral (OR = 2.04, 95% CI: 1.20–3.44) and herbal
(OR = 1.86, 95% CI: 1.04–3.34) medications more often relative to patients with less severe HRQoL impairment.
Conclusions: HRQoL in patients with psoriasis was significantly associated with their demographic and socioeconomic
characteristics and employment status. The presence of psoriasis on exposed areas of the body was significantly
associated with patients’ HRQoL and employment status. Further research is required to evaluate the impact of
psoriasis on patients’ productivity.
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Background
Psoriasis is a multisystem inflammatory disease that is
underdiagnosed and undertreated despite its prevalence
and considerable effect on quality of life (QoL). Beyond
skin and joint involvement, psoriasis is also associated
with various important medical and psychiatric condi-
tions that require timely therapy to improve long-term
outcomes [1]. Psoriasis is one of the most common
chronic skin diseases, affecting a large proportion of the
population [2]. Korea National Health Insurance data
showed that the number of patients with psoriasis in
Korea was 168,862 in 2013 and had increased by 1.5%
per year for 5 years from 2011 to 2016. Consequently,
the economic burden of disease for psoriasis has also in-
creased from 11 million USD to 21 million USD during
this period [3]. Despite this increase in the number of
patients and burden of disease for psoriasis, the miscon-
ception that skin diseases are less serious relative to
other illnesses remains.
Skin diseases, including psoriasis, have been shown to
exert a significant adverse effect on patients’ health-related
quality of life (HRQoL). Psoriasis can influence various as-
pects of patients’ lives including their careers, incomes, re-
lationships, and physical intimacy [4, 5]. It can increase in
severity, and moderate-to-severe psoriasis could com-
promise patients’ QoL considerably [6].
Psoriasis could lead to different types of stressful experi-
ence for patients [7]. Literature reviews have documented
various difficulties in coping with the chronic disease, in-
cluding those concerning treatment management, symp-
tom control, management of assaults on body image and
self-esteem, and the potential to lead a normal life [8]. In-
dividuals differ in their adjustment to a chronic illness. Pa-
tients with psoriasis report that the condition has various
psychosocial consequences, such as social isolation and
feelings of anger, depression, shame, and anxiety [9].
Improvement in QoL is an important treatment goal
for patients with psoriasis [10]. HRQoL measures are
particularly important for dermatological conditions, as
although not usually life-threatening, they frequently
exert a strong influence on patients’ psychosocial status,
social relationships, and everyday activities. The Body
Surface Area (BSA) tool is used to measure patients’
health status; however, objective clinical severity is not
always linearly associated with patients’ subjective dis-
tress, as one might expect [11].
Therefore, this national study aimed to identify the socio-
economic and clinical characteristics affecting HRQoL in
patients with psoriasis, using Internet-based questionnaires.
Methods
Study design and setting
We conducted a cross-sectional study between March
and June 2015, using data obtained via an Internet-based
survey in Korea. Participants’ socioeconomic and clinical
characteristics and HRQoL were examined simultan-
eously using a structured questionnaire.
Study participants and data collection
The participants were recruited via e-mail and invited to
participate in the survey in cooperation with the Korea
Psoriasis Association, a nationwide patient association with
17,092 members as of 2015. An invitation letter was sent to
1685 members who had registered for the Association at
least once in the past three years as a regular member and
were aged 19 years or older (at time of registration). Those
invited were informed that they could withdraw their con-
sent at any time during the study without incurring any
negative consequences and that their data would be ex-
cluded from the study. This study included a total of 299
patients (response rate was 17.7%) who (a) were diagnosed
with psoriasis at a clinic or a hospital, (b) signed an
informed consent form, and (c) answered all ques-
tions. The study protocol was reviewed and approved by
the Institutional Review Board at Chung-Ang University
(IRB Number: 1041078–201,501-HRSB-007-01).
Measurement
The independent variables included demographic, socio-
economic, and clinical characteristics. Demographic and
socioeconomic characteristics included gender, age,
marital status, educational level, employment status, an-
nual income, occupation, difficulty securing employment
because of psoriasis, and psoriasis-related resignation
from work.
Clinical characteristics were examined in terms of dur-
ation, severity, affected area of the body, and treatment.
Psoriasis severity was assessed according to the BSA af-
fected by psoriasis, using the question “How many times
the size of your palm is the entire area in which you have
psoriasis?” This measurement was based on the assump-
tion that one’s own palm area represents 1% of one’s BSA
[12]. Those with affected BSAs of 10% or larger, 5% to 9%,
and 5% or less were classified as patients with severe,
moderate, and mild psoriasis, respectively [12, 13].
The Dermatology Life Quality Index (DLQI) was used
to evaluate patients’ psoriasis-related HRQoL impair-
ment. The DLQI is a dermatology-specific QoL measur-
ing instrument consisting of 10 questions asking
patients to indicate how their skin disease has affected
their HRQoL during the preceding week. The sum of
the item scores provides a total score between 0 (no im-
pact on HRQoL) and 30 (maximum impact on HRQoL)
[14–16]. Scores of 11 or higher indicate severe HRQoL
impairment. This survey employed a Korean version of
DLQI which was validated by the Korean research team
and added as a reference to the study [17].
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Statistical analysis
Participants’ characteristics are presented as frequencies
and proportions for categorical variables and means and
standard deviations for continuous variables. Differences
were evaluated using chi-squared tests and t tests, as
appropriate.
Patients’ DLQI scores were classified into the follow-
ing five groups: Group 1: participants who reported no
effects (scores 0–1), Group 2: participants who reported
mild effects (scores 2–5), Group 3: participants who re-
ported moderate effects (scores 6–10), Group 4: partici-
pants who reported severe effects (score 11–20), and
Group 5: participants who reported very severe effects
(scores 21–30), and frequencies and proportions were
calculated for each group [18].
Analyses of variance or t tests were performed to com-
pare mean DLQI scores, and a chi-squared test was per-
formed to assess the association of demographic,
socioeconomic, and clinical factors with HRQoL in pa-
tients with scores of 11 or higher. Factors influencing
impairment were identified using multivariate logistic re-
gression analysis with backward elimination of factors
with clinical/socioeconomic significance that included
gender, age group (< 40 years, ≥40 years), psoriasis sever-
ity (BSA < 10%, BSA ≥ 10%), annual income (< 48,000
USD, ≥ 48,000 USD), resignation from work because of
psoriasis, psoriasis on the neck, use of oral medication
for psoriasis, and use of herbal medication for psoriasis.
Results
Among 1685 patients invited via e-mail, 299 patients
voluntarily participated in this survey (response rate,
17.7%). Table 1 shows participants’ characteristics ac-
cording to gender. Of the 299 participants, 224 (74.9%)
were men, who were more likely to be older, married, in
full-time employment, and earning higher incomes, rela-
tive to women. In addition, women tended to be more
likely to have psoriasis on the neck and less likely to re-
ceive topical treatment relative to men.
Participants’ mean DLQI score was 12.4 (SD = 7.6),
and 53.8% (n = 161) exhibited severe HRQoL impair-
ment (DLQI scores ≥11). Specifically, the proportions of
participants in Groups 1 2, 3, 4, and 5 were 4.0%, 16.7%,
25.4%, 37.1%, and 16.7%, respectively (Fig. 1).
Table 2 shows the participants’ DLQI scores according
to their demographic and socioeconomic characteristics.
The factors associated with high DLQI scores included
female gender and age younger than 40 years, divorce or
widowhood, education to high school level or lower,
part-time or temporary employment or unemployment,
and low income. In addition, DLQI scores were highest
in patients who reported that they always or often expe-
rienced difficulty securing employment and resigned
from work because of psoriasis.
Patients with severe psoriasis (BSA ≥ 10%) exhibited
high DLQI scores (15.0 ± 8.0), indicating severe HRQoL
impairment (Table 3). Further, DLQI scores in patients
with psoriasis on the face, neck, shoulder, or foot were
significantly higher relative to those observed in patients
with psoriasis on other areas of the body (p < .001). Pa-
tients who used oral or herbal medication exhibited
greater HRQoL impairment relative to those who did
not use these medications (p < .05).
The proportion of HRQoL impairment level observed
in women was twice that observed in men (odds ratio
[OR] = 2.00, 95% confidence interval [CI]: 1.05–3.80).
Patients with psoriasis on the neck exhibited signifi-
cantly greater HRQoL impairment relative to those with
psoriasis in other areas of the body (OR = 2.30, 95% CI:
1.20–4.43). Regarding socioeconomic status, patients
who earned 40 million KRW (approximately 48,000
USD) or more showed lower levels of HRQoL impair-
ment than those who had lower incomes (OR = 0.47,
95% CI: 0.28–0.80). Patients with severe HRQoL im-
pairment used oral (OR = 2.04, 95% CI: 1.20–3.44) or
herbal (OR = 1.86, 95% CI: 1.04–3.34) medications
more frequently than those with less severe HRQoL
impairment (Table 4).
Discussion
The results showed that HRQoL in patients with psoria-
sis was significantly associated with their demographic
and socioeconomic characteristics and employment sta-
tus. In addition, the presence of psoriasis on exposed
areas was significantly associated with patients’ HRQoL
and employment status. Visibility is associated with
self-esteem because appearance plays an important role
in social and cultural settings [19]. However, the overall
Psoriasis Area Severity Index (PASI) score is weighted
only by regional body surface area (BSA), failing to ac-
count for a disproportionate burden in more visible/sen-
sitive locations [7, 8]. Given that the burden of psoriasis
may be related to disease location and associated with
QoL [8], further research examining the impact of psor-
iasis on patient productivity is required.
Psoriasis has been associated with significant psycho-
logical distress, psychiatric morbidity, stigma, and reduc-
tions in HRQoL [20]. In addition, the clinical severity of
the condition, measured using the PASI, has been asso-
ciated with patients’ QoL [21]. In the current study, the
results showed that women were more likely to feel dis-
tressed or embarrassed about psoriasis relative to men.
This finding is consistent with those of previous research
conducted by Finlay et al., wherein men found it easier
to cope with the social effects of psoriasis than women
[22, 23]. Furthermore, stress research has provided an
additional method for enhancing the understanding of
differences between reactions of men and women’s
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Table 1 Characteristics of study participants with psoriasis by gender
Variables Total (n = 299) Male (n = 224) Female (n = 75)





Mean, SD 43.8 ±9.9 45.3 ±9.7 39.2 ±9.4 < 0.001
20–39 95 (31.8) 57 (25.4) 38 (50.7) < 0.001
40–59 181 (60.5) 146 (65.2) 35 (46.7)
60–79 23 (7.7) 21 (9.4) 2 (2.7)
Marital status
Single 75 (25.1) 48 (21.4) 27 (36.0) 0.038
Married 196 (65.6) 155 (69.2) 41 (54.7)
Divorced/widowed 26 (8.7) 21 (9.4) 7 (9.3)
Education level
≤ High school 65 (21.7) 43 (19.2) 22 (29.3) 0.143
College 183 (61.2) 145 (64.7) 40 (53.3)
Graduate school 49 (16.4) 36 (16.1) 13 (17.3)
Employment status
Full-time 213 (71.2) 171 (76.3) 42 (56.0) 0.003
Part-time 27 (9.0) 18 (8.0) 9 (12.0)
Unemployed/student/housewife 59 (19.7) 35 (15.6) 24 (32.0)
Annual income (USD)
< 24,000 33 (11.0) 20 (8.9) 13 (17.3) 0.003
24,000-47,999 99 (33.1) 71 (31.7) 34 (45.3)
48,000-71,999 92 (30.8) 72 (32.1) 20 (26.7)
≥ 72,000 69 (23.1) 61 (27.2) 8 (10.7)
Duration of psoriasis (years)
Mean, SD 21.3 ±10 21.6 ±9.7 20.5 ±10.8 0.426
1–9 33 (11.0) 21 (9.4) 12 (16.0) 0.429
10–19 113 (37.8) 88 (39.3) 25 (33.3)
20–29 89 (29.8) 67 (29.9) 22 (29.3)
≥ 30 64 (21.4) 48 (21.4) 16 (21.3)
Severity of psoriasis (BSA)
Mild (< 5%) 146 (48.8) 106 (47.3) 40 (53.3) 0.665
Moderate (5–9%) 65 (21.7) 50 (22.3) 15 (20.0)
Severe (≥10%) 88 (29.4) 68 (30.4) 20 (26.7)
Site of psoriasis
Head 233 (77.9) 179 (79.9) 54 (72.0) 0.153
Face 141 (47.2) 107 (47.8) 34 (45.3) 0.715
Neck 82 (27.4) 51 (22.8) 31 (41.3) 0.002
Shoulder 115 (38.5) 89 (39.7) 26 (34.7) 0.435
Chest/abdomen 191 (63.9) 141 (62.9) 50 (66.7) 0.562
Back/buttocks 232 (77.6) 174 (77.7) 58 (77.3) 0.951
Arm 229 (76.6) 169 (75.4) 60 (80.0) 0.420
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toward psoriasis and indicated that women are more
susceptible to stress [24, 25]. Consequently, stress is
more likely to exert a stronger impact on the psycho-
logical aspects of HRQoL in women than men [26].
Therefore, the findings of this present study are congru-
ent with those of previous studies. Moreover, some pre-
vious studies have shown that women were more likely
to react to stress and the displayed greater discomfort
and stigmatization than men [25, 27]. In addition, gen-
der differences were observed in Short Form-12 mental
component summary scores but not in general physical
or skin-related HRQoL [25].
With respect to financial status, a meaningful difference
in HRQoL was observed between participants with annual
incomes greater than 40 million KRW (48,000 USD) and
those with annual incomes less than that. The Korean
government established a maximum out-of-pocket pay-
ment limit to reduce patients’ financial burden resulting
from excessive medical expenses. This established limit is
designed to cover excesses above the individual limit by
income level and is implemented through the National
Health Insurance Service. However, under the system, pa-
tients with low income cannot take advantage of their in-
surance benefit because they may have to pay a substantial
out-of-pocket medical fee for psoriasis treatment and wait
for 20 months for their refund. This may make it difficult
to access more expensive and effective treatment options,
such as biologics, which can lead to low QoL [18].
Additionally, patients’ job security is dependent on
their disease severity, as it reduces their ability to work
and may lead to early retirement [28]. In a previous
study, patients with moderate-to-severe psoriasis were
estimated to experience a significant (15–20%) reduction
in their ability to work following diagnosis [29]. In an-
other study, participants’ productivity scores were nega-
tively associated with disease severity, indicating greater
impairment in patients with severe psoriasis, as they ex-
perienced symptoms of greater intensity and a larger re-
duction in HRQoL and productivity, relative to those
experienced by patients with mild or moderate psoriasis
Table 1 Characteristics of study participants with psoriasis by gender (Continued)
Variables Total (n = 299) Male (n = 224) Female (n = 75)
N (%) N (%) N (%) P-value
Hand 141 (47.2) 111 (49.6) 30 (40.0) 0.151
Leg 263 (88.0) 201 (89.7) 62 (82.7) 0.104
Foot 128 (42.8) 95 (42.4) 33 (44.0) 0.810
Treatment for psoriasis
Topical treatment 246 (82.3) 190 (84.8) 56 (74.7) 0.046
Prescribed oral medication 135 (45.2) 97 (43.3) 38 (50.7) 0.267
Herbal medication 88 (29.4) 62 (27.7) 26 (34.7) 0.250
Phototherapy 142 (47.5) 110 (49.1) 32 (42.7) 0.334
Injections except biologics 45 (15.1) 31 (13.8) 14 (18.7) 0.312
Biological therapy 28 (9.4) 22 (9.8) 6 (8.0) 0.639
BSA body surface area
Fig. 1 Distribution of Dermatology Life Quality Index (DLQI) score (%)
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[30]. Therefore, physicians should be mindful of the im-
pact of severe disease on patients’ lives, including em-
ployment, and endeavor to address this issue.
In recent literature, attention has been focused on the
role of psychological factors in the frequency of recur-
rence and remission, and treatment dynamics [31] be-
cause the skin is important to aesthetics and appearance.
It is also an important factor in nonverbal communica-
tion and interpersonal relationships, partly because it is
involved in emotional expression. Therefore, chronic
dermatological conditions exert a significant effect on
patients’ psychological health, self-esteem, and body
image. Understandably, patients are very anxious about
psoriasis on the neck, as it is difficult to conceal from
Table 2 DLQI Scores according to demographic and socioeconomic factors in patients with psoriasis
Variables No. of
patients
DLQI Scores p-value DLQI ≤10 DLQI ≥11 p-value
Mean ± SD N (%) N (%)
Total participants 299 12.4 ± 7.6 138 (46.2) 161 (53.8)
Gender
Male 224 11.6 ± 7.5 0.003 117 (52.2) 107 (47.8) < 0.001
Female 75 14.7 ± 7.7 21 (28.0) 54 (72.0)
Age (years)
20–39 95 13.9 ± 8.2 0.038 38 (40.0) 57 (60.0) 0.258
40–59 181 11.9 ± 7.2 87 (48.1) 94 (51.9)
60–79 23 10.3 ± 7.5 13 (56.5) 10 (43.5)
Marital status
Single 75 14.7 ± 8.3 < 0.001 29 (38.7) 46 (61.3) 0.009
Married 196 11.0 ± 6.9 102 (52.0) 94 (48.0)
Divorced/widowed 28 15.9 ± 8.0 7 (25.0) 21 (75.0)
Education level
≤ High school 65 14.8 ± 7.4 0.010 21 (32.3) 44 (67.7) 0.029
College 183 11.5 ± 7.4 95 (51.9) 90 (49.2)
Graduate school 49 12.6 ± 8.0 22 (44.9) 27 (55.1)
Employment status
Full-time 213 11.4 ± 7.2 0.002 106 (49.8) 107 (50.2) 0.127
Part-time 27 15.8 ± 8.2 9 (33.3) 18 (66.7)
Unemployed/student/housewife 59 14.3 ± 8.1 23 (39.0) 36 (61.0)
Type of employment
Employer or self-employed 59 11.2 ± 6.8 < 0.001 31 (52.5) 28 (47.5) 0.098
Regular job 159 11.4 ± 7.2 78 (49.1) 81 (50.9)
Temporary job 17 18.2 ± 8.8 4 (23.5) 13 (76.5)
Unemployed 64 14.5 ± 8.0 25 (39.1) 39 (60.9)
Annual income (USD)
< 24,000 33 18.3 ± 8.3 < 0.001 7 (21.2) 26 (78.8) < 0.001
24,000-47,999 105 13.9 ± 7.2 38 (36.2) 67 (63.8)
48,000-71,999 92 10.7 ± 7.3 49 (53.3) 43 (46.7)
≥ 72,000 69 9.5 ± 6.2 44 (63.8) 25 (36.2)
Experience of difficulty in finding jobs due to psoriasis
Always/often 87 17.9 ± 7.3 < 0.001 15 (17.2) 72 (82.8) < 0.001
Somewhat/sometimes/never 212 10.1 ± 6.5 123 (58.0) 89 (42.0)
Experience of quitting jobs due to psoriasis
Yes 92 15.9 ± 8.0 < 0.001 23 (25.0) 69 (75.0) < 0.001
No/Inapplicable 207 10.8 ± 6.9 115 (55.6) 92 (44.4)
DLQI Dermatology life quality index
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Table 3 DLQI Scores by clinical factors in patients with psoriasis
Variables No. of
patients
DLQI Scores p-value DLQI ≤10 DLQI ≥11 p-value
Mean ± SD N (%) N (%)
Total participants 299 12.4 ± 7.6 138 (46.2) 161 (53.8)
Duration of psoriasis (years)
1–9 33 14.8 ± 8.3 0.201 14 (42.4) 19 (57.6) 0.661
10–19 113 12.6 ± 7.8 50 (44.2) 63 (55.8)
20–29 89 11.5 ± 7.6 46 (51.7) 43 (48.3)
≥ 30 64 12.0 ± 6.9 28 (43.8) 36 (56.3)
Severity of psoriasis (BSA)
Mild (< 5%) 146 10.5 ± 6.9 < 0.001 80 (54.8) 66 (45.2) 0.005
Moderate (5–9%) 65 13.0 ± 7.6 29 (44.6) 36 (55.4)
Severe (≥10%) 88 15.0 ± 8.0 29 (33.0) 59 (67.0)
Site of psoriasis
Head 233 13.0 ± 7.8 0.010 101 (43.3) 132 (56.7) 0.067
Face 141 14.4 ± 8.2 < 0.001 54 (38.3) 87 (61.7) 0.010
Neck 82 16.0 ± 7.5 < 0.001 21 (25.6) 61 (74.4) < 0.001
Shoulder 115 15.2 ± 7.8 < 0.001 41 (35.7) 74 (64.3) 0.004
Chest/abdomen 191 13.5 ± 7.6 0.001 74 (38.7) 117 (61.3) 0.001
Back/buttocks 232 13.5 ± 7.7 < 0.001 93 (40.1) 139 (59.9) < 0.001
Arm 229 13.2 ± 7.8 0.001 97 (42.4) 132 (57.6) 0.017
Hand 141 14.2 ± 7.7 < 0.001 51 (36.2) 90 (63.8) 0.001
Leg 263 12.4 ± 7.7 0.916 120 (45.6) 143 (54.4) 0.622
Foot 128 14.7 ± 7.6 < 0.001 43 (33.6) 85 (66.4) < 0.001
Treatment for psoriasis
Topical treatment 246 12.8 ± 7.6 0.048 107 (43.5) 139 (56.5) 0.047
Prescribed oral medication 135 14.8 ± 7.9 < 0.001 44 (32.6) 91 (67.4) < 0.001
Herbal medication 88 14.2 ± 7.8 0.009 30 (34.1) 58 (65.9) 0.007
Phototherapy 142 13.8 ± 8.1 0.002 57 (40.1) 85 (59.9) 0.047
Injections except biologics 45 15.1 ± 8.6 0.011 16 (35.6) 29 (64.4) 0.122
Biological therapy 28 11.8 ± 8.9 0.636 14 (50.0) 14 (50.0) 0.668
DLQI Dermatology life quality index; BSA: body surface area
Table 4 Factors influencing HRQoL impairment
Variables Crude odds ratio (95% CI) Adjusted odds ratio (95% CI)
Female 2.812 (1.593–4.963) 1.996 (1.048–3.800)
Age of 40 years or older 0.693 (0.423–1.136) 1.311 (0.719–2.389)
BSA≥ 10% 2.174 (1.292–3.657) 1.383 (0.739–2.589)
Annual income ≥ USD 48,000 0.354 (0.220–0.568) 0.471 (0.276–0.804)
Experience of quitting jobs due to psoriasis 3.750 (2.173–6.472) 2.158 (1.172–3.972)
Psoriasis on neck 3.399 (1.935–5.969) 2.304 (1.199–4.428)
Use of oral drugs for psoriasis 2.777 (1.728–4.464) 2.036 (1.204–3.443)
Use of oriental medicines for psoriasis 2.027 (1.209–3.399) 1.859 (1.035–3.341)
Dermatology life quality index cutoff score for severe quality of life impairment: ≥11, HRQoL health-related quality of life, BSA body surface area,
CI confidence interval
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others. Chronic stress and the related loss of positive
self-image could also lead to social rejection, which is
likely to exacerbate psoriatic symptoms [32]. Conse-
quently, stress could be considered a prognostic factor
for psychosocial dysfunction in patients with psoriasis.
Moreover, reduction of emotional well-being in propor-
tion to the severity of skin changes could lead to reduc-
tions in subjective QoL and psychological functioning.
With respect to treatment, topical therapy, such as
steroid cream or lotion, is frequently used to treat mild
or moderate psoriasis. In addition, anthralin, tar, vitamin
D derivatives (i.e., calcipotriol), and vitamin A (i.e., tazar-
otene) are popular oral medications, and systemic treat-
ment for severe psoriasis includes methotrexate and
cyclosporine as standard medication options in Korea.
However, systemic treatments are likely to include side
effects, such as clinically significant liver enzyme abnor-
malities, which could influence patients’ QoL.
Psoriasis patients often enquire about the use of nu-
merous herbal and oriental medicines; therefore, derma-
tologists should keep abreast of contemporary evidence
regarding these agents. However, health professionals
are cautious in their use of herbal medications, particu-
larly those for psoriasis, because of availability and qual-
ity issues identified via research [33].
This research was conducted with a limited number of
patients who were registered in a patient group. In
addition, the participants completed the questionnaires
online; consequently, the study was restricted to patients
who were available and able to use the Internet and a
computer, which could have led to response bias and
limited the generalizability of the findings to other pa-
tient groups. Furthermore, according to a previous
study, in South Korea as of 2015, the male-to-female ra-
tio of patients with psoriasis was 1.3:1, and the percent-
age of elderly patients over 60 years old with psoriasis
was 25% [34]. Compared with the entire psoriasis popu-
lation, the present study included fewer women (25.1%)
with a lower QoL, and the results may be underesti-
mated. On the other hand, there is a possibility that the
results are overestimated because of the inclusion of
fewer elderly people (7.7%) with a higher QoL. In terms
of research design, these findings could not explain the
robust causal inference because this study was per-
formed using a cross-sectional design and may only able
to provide snapshots of psoriasis patients’ current situa-
tions. In addition, further research is required to exam-
ine the impact of psoriasis on patient productivity.
Conclusion
Treatment goals and success should be based on pa-
tients’ QoL in the provision of patient-centered care.
However, treatment outcomes can be measured easily
using objective criteria such as the Patient Benefit Index
global score and the PASI. Therefore, patients’ demo-
graphic and socioeconomic characteristics and employ-
ment status may be ignored, despite being significantly
associated with psoriasis patients’ HRQoL. Patients’ em-
ployment status and the presence of psoriasis in exposed
areas could be significantly associated with their QoL
and satisfaction with treatment. Through this research,
it was shown that HRQoL of psoriasis patients was a
major factor in managing the disease. Therefore, when
physicians and patients set treatment goals together, key
factors affecting QoL should be considered.
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